Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Randomized Study to Determine Whether Use of Rhopressa Accelerates Corneal Clearing After Removal of Descemet Membrane for Treatment of Fuchs Dystrophy

Next Previous
Trial Profile

Prospective Randomized Study to Determine Whether Use of Rhopressa Accelerates Corneal Clearing After Removal of Descemet Membrane for Treatment of Fuchs Dystrophy

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netarsudil (Primary)
  • Indications Fuchs' endothelial dystrophy
  • Focus Pharmacodynamics

Most Recent Events

  • 28 Aug 2021 Status changed from active, no longer recruiting to discontinued.
  • 24 Aug 2021 Status changed from recruiting to active, no longer recruiting.
  • 03 Mar 2021 Planned End Date changed from 15 Jun 2021 to 15 Jun 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top